Institutional members access full text with Ovid®

Share this article on:

Immunotherapy for ovarian cancer: recent advances and perspectives

Zsiros, Emesea; Tanyi, Janosa; Balint, Klaraa; Kandalaft, Lana E.a,b

doi: 10.1097/CCO.0000000000000111
GYNECOLOGIC CANCER: Edited by Martin Gore

Purpose of review Epithelial ovarian cancer is the most frequent cause of gynecologic cancer-related mortality in women, and prognosis for patients with recurrent or metastatic disease is extremely poor. Therefore, there is an enormous unmet need for the development of novel therapies in this indication. Although surgery and chemotherapy can improve survival rates, it is necessary to integrate alternative strategies, such as immunotherapy to improve the outcomes for patients with advanced ovarian cancer.

Recent findings We will discuss the rationale of immunotherapy and some of the mechanisms of immunogenicity in ovarian cancer. We will highlight current results with cancer vaccines, adoptive T-cell therapy and immunomodulatory agents and will summarize the immune effects of selected chemotherapeutic agents, radiotherapy and recent results with combinatorial approaches in this disease setting. We will also discuss recent and potential future therapeutic interventions that might circumvent tumor-mediated immunosuppression.

Summary Dramatic increase in the number of immunotherapy clinical trials was seen in the past decade with promising results in enhancing antitumor immune response and cancer vaccine efficacy. The future challenge for immunotherapy against ovarian cancer is to use a combinatorial approach to test rational, potentially synergistic immunotherapy combinations that can induce efficient antitumor immunity and prolong patients’ survival.

aOvarian Cancer Research Center, Smilow Translational Research Center, Perelman School of Medicine of University of Pennsylvania Philadelphia, Pennsylvania, USA

bDepartment of Oncology, Ludwig Cancer Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Correspondence to Lana E. Kandalaft, PharmD, PhD, MTR, Department of Oncology, Ludwig Cancer Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Tel: +41 (0)21 314 78 23; e-mail: lknd@mail.med.upenn.edu, lana.kandalaft@chuv.ch

© 2014 Lippincott Williams & Wilkins, Inc.